Company Overview of Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
245 First Street
Cambridge, MA 02142
Founded in 2007
Key Executives for Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|Primordial Genetics, Inc.||United States|
|Silver Creek Pharmaceuticals, Inc.||United States|
|Molecular Biosystems, Inc||United States|
|Juvaris BioTherapeutics, Inc.||United States|
|BiosPacific, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Akebia Therapeutics, Inc., please visit www.akebia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.